Abvc Biopharma (ABVC) Cash & Equivalents (2009 - 2026)
Abvc Biopharma's Cash & Equivalents came in at $11,294 for Q3 2026, down 94.1% from $192,068 a year earlier and down 64.6% from the prior quarter.
Powered by 
Analysis
Abvc Biopharma (ABVC) Cash & Equivalents (2009 - 2026) Analysis & Trends
At the end of FY2025, Abvc Biopharma's Cash & Equivalents was $681,480, up 174.4% from FY2024.
- Cash & Equivalents carries a five-year compound annual growth rate of -30.7% (FY2020 to FY2025).
- Going back by year, Cash & Equivalents was $248,382 in FY2024 (+312.9%), $60,155 in FY2023 (-95.7%), $1.39 million in FY2022 (-78.8%) and $6.57 million in FY2021 (+53.6%).
- The Q3 2026 figure represents the lowest quarterly Cash & Equivalents since Q3 2018.
- Year-over-year, Cash & Equivalents has declined for three consecutive quarters, with growth averaging 58.6% over the last eight quarters.
- The fastest year-over-year change in Cash & Equivalents over five years came in Q4 2024 (growth of 312.9%), and the weakest in Q2 2023 (a decline of 96.6%).
- Business Quant data shows ABVC's Cash & Equivalents at $31,944 (Q2 2026), $140,324 (Q1 2026) and $681,480 (Q4 2025) in the three quarters before Q3 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 4.89 Bn |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 10.77 Bn |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 9.55 Bn |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | 400.00 Mn |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 7.94 Bn |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 13.19 Bn |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | 6.44 Bn |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 1.82 Bn |
| 10 | Abvc Biopharma | 24.28 Mn | 21.86 Mn | - | 11,294.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 11,294.00 |
| Jun 30, 2026 | 31,944.00 |
| Mar 31, 2026 | 140,324.00 |
| Dec 31, 2025 | 681,480.00 |
| Sep 30, 2025 | 192,068.00 |
| Jun 30, 2025 | 388,251.00 |
| Mar 31, 2025 | 152,206.00 |
| Dec 31, 2024 | 248,382.00 |
| Sep 30, 2024 | 137,344.00 |
| Jun 30, 2024 | 124,296.00 |
| Mar 31, 2024 | 659,002.00 |
| Dec 31, 2023 | 60,155.00 |
| Sep 30, 2023 | 1.12 Mn |
| Jun 30, 2023 | 99,290.00 |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 1.39 Mn |
| Sep 30, 2022 | 1.97 Mn |
| Jun 30, 2022 | 2.91 Mn |
| Mar 31, 2022 | 2.72 Mn |
| Dec 31, 2021 | 6.57 Mn |
API Access
Abvc Biopharma Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ABVC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "ABVC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ABVC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();